Program
vorasidenib
Also written as “Vorasidenib”, “AG881” and “AG-881”.
Its studies are mostly in Astrocytoma · Glioma · Leukemia, Myeloid, Acute, led by 5 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Agios Pharmaceuticals | 50 open or running | phase 1since Jul 6, 2015 | Jul 6, 2015 | none ahead |
| Institut de Recherches Internationales Servier (I.R.I.S.) | 42 open or running | phase 2since Dec 10, 2025 | Nov 14, 2025 | Nov 23, 2026phase 1 · NCT07250633 |
| Servier | 11 open or running | phase 3since Dec 24, 2024 | Dec 24, 2024 | none ahead |
| Servier (Tianjin) Pharmaceutical | 11 open or running | no phasesince Apr 29, 2025 | Apr 29, 2025 | Apr 2028NCT06969352 |
| Servier Bio-Innovation | 10 open or running | phase 1since Apr 19, 2023 | Apr 19, 2023 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 6, 2015First study: phase 1 study in Leukemia, Myeloid, AcuteNew to Agios PharmaceuticalsAgios Pharmaceuticals · NCT02492737 · 46 enrolled · United States, France
- May 21, 2019Phase 1 study in Healthy Male ParticipantsAgios Pharmaceuticals · NCT03960502 · 5 enrolled · United States
- Jul 3, 2019Phase 1 study in Healthy ParticipantsAgios Pharmaceuticals · NCT04015687 · 22 enrolled · United States
- Oct 4, 20192 phase 1 studies in Healthy VolunteersAgios Pharmaceuticals · NCT04128787, NCT04145128
- Apr 19, 2023Servier Bio-Innovation's first study: phase 1 study in Healthy SubjectsNew to Servier Bio-InnovationServier Bio-Innovation · NCT05843708 · 64 enrolled · United States
- Dec 24, 2024Servier's first study: phase 3 study in Residual or Recurrent Grade 2 IDH Mutant GliomaNew to ServierServier · NCT06780930 · 57 enrolled · China, Taiwan
- Apr 29, 2025Servier (Tianjin) Pharmaceutical's first study: no phase study in GliomaNew to Servier (Tianjin) PharmaceuticalServier (Tianjin) Pharmaceutical · NCT06969352 · 62 enrolled · China
- Nov 14, 2025Institut de Recherches Internationales Servier (I.R.I.S.)'s first studies: 3 phase 1 studiesNew to Institut de Recherches Internationales Servier (I.R.I.S.)Institut de Recherches Internationales Servier (I.R.I.S.) · NCT07235774, NCT07235748, NCT07250633
- Dec 10, 2025Phase 2 study in Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 MutationPhase 2 reachedInstitut de Recherches Internationales Servier (I.R.I.S.) · NCT07286292 · 10 planned · United States, Australia, Canada
Ahead
- Nov 23, 2026Primary completion: phase 1 study in Severe Hepatic ImpairmentInstitut de Recherches Internationales Servier (I.R.I.S.) · NCT07250633
- Apr 2028Primary completion: no phase study in GliomaServier (Tianjin) Pharmaceutical · NCT06969352
- May 2, 2033Primary completion: phase 2 study in Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 MutationInstitut de Recherches Internationales Servier (I.R.I.S.) · NCT07286292
TargetBeta
“An orally available inhibitor of mutated forms of both isocitrate dehydrogenase type 1 (IDH1, IDH1 [NADP+] soluble) in the cytoplasm and type 2 (IDH2, isocitrate dehydrogenase [NADP+], mitochondrial) in the mitochondria, ”NCIt, by rule
“IDH1/IDH2 inhibitor; Isocitrate dehydrogenase [NADP], mitochondrial inhibitor; Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ranosidenibrule | HUTCHMED | phase 3 | 7 |
Studies
All 12 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07286292Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation · United States, Australia, Canada | 2 | Recruiting | Institut de Recherches Internationales Servier (I.R.I.S.) | May 2, 2033 | 10 |
| NCT07250633Severe Hepatic Impairment · United States | 1 | Recruiting | Institut de Recherches Internationales Servier (I.R.I.S.) | Nov 23, 2026 | 20 |
| NCT07235774Healthy Adult Female Participants · United Kingdom | 1 | Completed | Institut de Recherches Internationales Servier (I.R.I.S.) | Mar 13, 2026 | 28 |
| NCT07235748Healthy Adult Participants · United Kingdom | 1 | Completed | Institut de Recherches Internationales Servier (I.R.I.S.) | Dec 23, 2025 | 28 |
| NCT06969352Glioma · China | – | Active, not recruiting | Servier (Tianjin) Pharmaceutical | Apr 2028 | 62 |
| NCT06780930Residual or Recurrent Grade 2 IDH Mutant Glioma · China, Taiwan | 3 | Active, not recruiting | Servier | May 7, 2026 | 57 |
| NCT05843708Healthy Subjects · United States | 1 | Completed | Servier Bio-Innovation | Jul 28, 2023 | 64 |
| NCT04145128Healthy Volunteers · United States | 1 | Completed | Agios Pharmaceuticals | Dec 11, 2019 | 32 |
| NCT04128787Healthy Volunteers · United States | 1 | Completed | Agios Pharmaceuticals | Dec 18, 2019 | 36 |
| NCT04015687Healthy Participants · United States | 1 | Completed | Agios Pharmaceuticals | Oct 9, 2019 | 22 |
| NCT03960502Healthy Male Participants · United States | 1 | Completed | Agios Pharmaceuticals | Sep 7, 2019 | 5 |
| NCT02492737Leukemia, Myeloid, Acute · United States, France | 1 | Completed | Agios Pharmaceuticals | Mar 21, 2018 | 46 |
How it is read
Names in the registry
- “Vorasidenib”, 5 entries
- “AG881”, 2 entries
- “AG-881”, 2 entries
- “Vorasidenib 20mg”, 1 entry
- “Vorasidenib 40 mg Oral Tablet”, 1 entry
Conditions, from the studies’ own filings
- Astrocytoma, 1 study
- Glioma, 1 study
- Leukemia, Myeloid, Acute, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.